The quantified method for blood clot detection in the extraction socket

F1000Res. 2024 Sep 10;13:1043. doi: 10.12688/f1000research.155330.1. eCollection 2024.ABSTRACTBACKGROUND: Currently, there is no objective and quantified measurement for detecting blood clots during extraction socket hemostasis. It has relied solely on clinical observation, even when conducting clin

S Suwat Tanya

Comparative Analysis of Treatment Outcomes and Prognostic Factors in Early T-Precursor Versus Non-ETP Acute Lymphoblastic Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults

Transplant Proc. 2025 Mar 17:S0041-1345(25)00129-0. doi: 10.1016/j.transproceed.2025.02.029. Online ahead of print.ABSTRACTThis study evaluates the outcomes and risk factors associated with allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adolescents and young adults (AYA) diagnosed

C Chengsen Cai

Evaluation of D-Dimer, P-Selectin, and miR-17-5p Expression in ICU and Non-ICU COVID-19 Patients: A Cross-sectional Study

Biochem Genet. 2025 Mar 18. doi: 10.1007/s10528-025-11062-x. Online ahead of print.ABSTRACTCOVID-19, caused by SARS-CoV-2 infection, frequently induces thrombotic complications in affected individuals. P-selectin, a pivotal platelet marker, plays a central role in platelet-leukocyte aggregation, con

V Vida Shirani Asl

The Use of Primary Care Physiotherapy for Persons With Bleeding Disorders in the Netherlands-A Retrospective Study of Health Records

Haemophilia. 2025 Mar 18. doi: 10.1111/hae.70034. Online ahead of print.ABSTRACTINTRODUCTION: Patients with musculoskeletal complaints as a result of their bleeding disorder can benefit from primary care physiotherapy. The current study aims to describe physiotherapy services provided in primary car

J Johan Blokzijl

The Iron Ladies: Prevalence and Risk Factors of Iron Deficiency in Females With Bleeding Disorders

Haemophilia. 2025 Mar 18. doi: 10.1111/hae.70004. Online ahead of print.ABSTRACTINTRODUCTION: Iron deficiency (ID) impairs cognitive and physical function. Females with bleeding disorders (FBD) are at risk of ID as a result of bleeding symptoms.AIM: This study aimed to report the overall incidence a

M Meghan McCormick

Perioperative Management With Efanesoctocog Alfa in Patients With Haemophilia A in the Phase 3 XTEND-1 and XTEND-Kids Studies

Haemophilia. 2025 Mar 18. doi: 10.1111/hae.70017. Online ahead of print.ABSTRACTINTRODUCTION: The Phase 3 studies, XTEND-1 (NCT04161495) and XTEND-Kids (NCT04759131), showed once-weekly efanesoctocog alfa provided high-sustained factor VIII (FVIII) activity levels that translated into highly effecti

R Robert Klamroth

Consequences of platelet-educated cancer cells on the expression of inflammatory and metastatic glycoproteins

PLoS One. 2025 Mar 17;20(3):e0317096. doi: 10.1371/journal.pone.0317096. eCollection 2025.ABSTRACTCancer-associated thrombosis, a major cause of mortality in cancer patients, exhibits a 4 to 7 times higher incidence compared to the general population. Platelet activation by tumor cells contributes t

M Mélanie Langiu

Anticoagulation Management: Current Landscape and Future Trends

J Clin Med. 2025 Feb 28;14(5):1647. doi: 10.3390/jcm14051647.ABSTRACTBlood transports nutrients and oxygen to the cells while removing the waste. It also possesses a hemostasis function to prevent excessive bleeding. However, abnormal clot formation (thrombosis) within healthy blood vessels can lead

A Andaleb Kholmukhamedov

Management of Bleeding, Thrombotic and Pregnancy-Related Complications in Women with Myeloproliferative Neoplasms: A Case-Based Review Focusing on Sex-Specific Challenges

J Clin Med. 2025 Feb 25;14(5):1537. doi: 10.3390/jcm14051537.ABSTRACTMyeloproliferative neoplasms (MPNs) are a heterogeneous group of clonal hematopoietic disorders that pose unique challenges in women, particularly regarding thrombosis, bleeding, fertility, and pregnancy. Women with MPN exhibit dis

T Thita Chiasakul

Dual Functionalized Absorbable Hairy Cellulose-Based Fabric for Efficient Hemostasis and Antibacterial Property

Adv Healthc Mater. 2025 Mar 17:e2404438. doi: 10.1002/adhm.202404438. Online ahead of print.ABSTRACTUncontrolled hemorrhage and subsequent infection at the injury sites are major causes of trauma-related mortality. Herein, we present a novel approach to creating a multifunctional biodegradable texti

N Nastaran Alipour

Intrinsic pathway activation in patients with antiphospholipid syndrome and healthy controls

Res Pract Thromb Haemost. 2025 Jan 31;9(1):102694. doi: 10.1016/j.rpth.2025.102694. eCollection 2025 Jan.ABSTRACTBACKGROUND: Antiphospholipid syndrome (APS) is a thrombotic autoimmune disease. Activation of the intrinsic coagulation pathway contributes to inflammatory and cardiovascular diseases, bu

D Dagmar J M van Mourik

Silencing of the von Willebrand factor gene in proatherothrombotic APOE∗3-Leiden.CETP transgenic mice

Res Pract Thromb Haemost. 2025 Feb 6;9(1):102699. doi: 10.1016/j.rpth.2025.102699. eCollection 2025 Jan.ABSTRACTBACKGROUND: Elevated von Willebrand factor (VWF) levels correlate with higher risk of atherosclerosis-related arterial thrombosis (atherothrombosis). Silencing the VWF gene via small-inter

Y Yvonne K Jongejan

Extracellular vesicles modulate endothelial nitric oxide production in patients with β‑thalassaemia/HbE

Biomed Rep. 2025 Feb 28;22(5):79. doi: 10.3892/br.2025.1957. eCollection 2025 May.ABSTRACTThrombosis is a significant complication in patients with β-thalassaemia/haemoglobin E (HbE), particularly in splenectomised patients. The endothelium is a key regulator of vascular haemostasis and homeostasis,

K Kunwadee Phongpao

Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance

J Thromb Haemost. 2025 Mar 14:S1538-7836(25)00150-3. doi: 10.1016/j.jtha.2025.02.042. Online ahead of print.ABSTRACTValoctocogene roxaparvovec is the only factor VIII (FVIII) gene therapy currently approved for adults with severe hemophilia A in Europe and the USA. Elevated alanine transaminase (tra

B Barbara A Konkle

The thrombin generation potential increases after feminizing gender affirming hormone treatment and decreases after masculinizing gender affirming hormone treatment and is determined by hormone treatment regimen

J Thromb Haemost. 2025 Mar 14:S1538-7836(25)00149-7. doi: 10.1016/j.jtha.2025.03.006. Online ahead of print.ABSTRACTBACKGROUND: The effects of gender affirming hormone therapy (GAHT) on the overall coagulation potential are not clarified. The global thrombin generation (TG) assay addresses the combi

M Mette Bøgehave

Reduced anticoagulation targets in extracorporeal life support (RATE): protocol for a pre-planned secondary Bayesian analysis of the rate trial

Trials. 2025 Mar 15;26(1):90. doi: 10.1186/s13063-025-08737-6.ABSTRACTBACKGROUND: The RATE trial is a three-arm non-inferiority randomized controlled trial in adult patients treated with extracorporeal membrane oxygenation (ECMO) on the effect of anticoagulation levels on mortality, hemorrhagic, and

O Olivier van Minnen

The derivatives of hirudin-like peptides from the Poecilobdella manillensis exhibit antithrombotic and anti-ischemic stroke effects

Int J Biol Macromol. 2025 Mar 12;307(Pt 3):141950. doi: 10.1016/j.ijbiomac.2025.141950. Online ahead of print.ABSTRACTAlmost all currently approved anticoagulants interfere with hemostasis and increase the risk of bleeding complications. Thus, there is a critical need for safer anti-thrombotic drugs

M Mehwish Khalid

Loss of factor VIII in zebrafish rebalances antithrombin deficiency but has a limited bleeding diathesis

Blood Adv. 2025 Mar 14:bloodadvances.2024013143. doi: 10.1182/bloodadvances.2024013143. Online ahead of print.ABSTRACTDeficiencies in coagulation factor VIII (FVIII, F8) result in the bleeding disorder hemophilia A. An emerging novel therapeutic strategy for bleeding disorders is to enhance hemostas

R Raghunath Azhwar

Direct Oral Anticoagulant Use in Older Adults with Atrial Fibrillation: Challenges and Solutions

Eur Cardiol. 2025 Feb 20;20:e03. doi: 10.15420/ecr.2024.17. eCollection 2025.ABSTRACTAF is the most common arrhythmia in clinical practice, with a large preponderance in the older (>75 years) adult population. Stroke is the most feared complication of AF, with huge corresponding morbidity and mortal

M Monika Bhandari

Non-O Blood Groups and Cardiovascular Outcomes in COVID-19: Findings From a Large Multicenter Study

No abstractJACC Adv. 2025 Mar 12;4(4):101641. doi: 10.1016/j.jacadv.2025.101641. Online ahead of print.NO ABSTRACTPMID:40080920 | DOI:10.1016/j.jacadv.2025.101641

H Hannah Leyva

Safety and Efficacy of the Use of pdVWF/FVIII-C in Patients with von Willebrand Disease: A Prospective, Observational, Post-Authorization Study

Clin Appl Thromb Hemost. 2025 Jan-Dec;31:10760296251327593. doi: 10.1177/10760296251327593. Epub 2025 Mar 13.ABSTRACTIntroductionPlasma-derived von Willebrand factor containing FVIII concentrates (pdVWF/FVIII-C) are indicated as replacement therapy for patients with von Willebrand disease (VWD). Thi

O Olga Benítez Hidalgo

Regulation of immune responses to therapeutic factor VIII by transplacental delivery of Fc-fused immunodominant factor VIII domains or peptides

Haematologica. 2025 Mar 13. doi: 10.3324/haematol.2024.287057. Online ahead of print.ABSTRACTPatients with severe hemophilia A (HA) often develop undesired immune responses to therapeutic factor VIII (FVIII) that hamper replacement therapy with FVIII-derived products. The transplacental delivery of

A Alejandra Reyes-Ruiz

Vitamin D Supplementation Effects on Markers Related with Endothelial Function and Coagulation in Obese Orthopedic Patients: Insights from Acute and Chronic Cases

Nutrients. 2025 Feb 28;17(5):882. doi: 10.3390/nu17050882.ABSTRACTObesity is a risk factor for thrombosis-related diseases and a condition that leads to vitamin D deficiency. Furthermore, orthopedic conditions are also at risk for diseases associated with coagulation and endothelial function. This s

M Michał Gawryjołek

Plasma miR-145-5p Levels and Risk of Future Cancer-Results from the HUNT Study

Int J Mol Sci. 2025 Feb 28;26(5):2191. doi: 10.3390/ijms26052191.ABSTRACTMicroRNA-145-5p (miR-145) has been reported to regulate multiple oncogenes and is considered a tumor suppressor. However, it remains unknown whether the level of plasma miR-145 can serve as a risk biomarker for future cancer. U

C Christopher Antoun